Novel Chiral Skeletons for Drug Discovery: Antibacterial Tetramic Acids

Chemical Biology and Drug Design

Volumn 78, Issue 2, 2011, Pages 229-235

  Holloway, Chloe A ^a   Matthews, Christopher J ^a   Jeong, Yong Chul ^a   Moloney, Mark G ^a   Roberts, Christine F ^a   Yaqoob, Muhammad ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Drug design; Molecular diversity; Natural product

Indexed keywords

SERINE; TETRAMIC ACID DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; CHIRALITY; DRUG ANALYSIS; DRUG DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; ESCHERICHIA COLI; MOLECULAR STRUCTURE; PYRROLIDINONES; STAPHYLOCOCCACEAE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79960381613     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01133.x     Document Type: Article

References (51)

1. Cheng C.C., Shipps G.W., Yang Z., Sun B., Kawahata N., Soucy K.A., Soriano A. et al. (2009) Discovery and optimization of antibacterial AccC inhibitors. Bioorg Med Chem Lett;19:6507-6514.
2. Galloway W.R.J.D., Bender A., Welch M., Spring D.R. (2009) The discovery of antibacterial agents using diversity-oriented synthesis. Chem Commun (Camb);18:2446-2462.
3. Yoshida M., Hedberg C., Kaiser M., Waldmann H. (2009) Traceless solid phase synthesis of natural product inspired cis-1, 2-dehydrodecalins. Chem Commun (Camb);20:2926-2928.
4. Grabowski K., Schneider G. (2007) Properties and architecture of drugs and natural products revisited. Curr Chem Biol;1:115-127.
5. Gullo V.P., McAlpine J., Lam K.S., Baker D., Petersen F. (2006) Drug discovery from natural products. J Ind Microbiol Biotechnol;33:523-531.
6. Rouhi A.M. (2003) The case for natural products research. Chem Eng News;81:77-91.
7. Breinbauer R.B., Vetter I.R., Waldmann H. (2002) From protein domains to drug candidates - Natural products as guiding principles in the design and synthesis of compound libraries. Angew Chem Int Ed Engl;41:2878.
8. Ganesan A. (2004) Natural products as a hunting ground for combinatorial chemistry. Curr Opin Biotechnol;15:584-590.
9. Njardarson J.T., Gaul C., Shan D., Huang X.-Y., Danishefsky S.J. (2004) Discovery of potent cell migration inhibitors through total synthesis: lessons from structure-activity studies of (+)-migrastatin. J Am Chem Soc;126:1038-1040.
10. vonNussbaum F., Brands M., Hinzen B., Weigand S., Habich D. (2006) Antibacterial natural products in medicinal chemistry-exodus or revival? Angew Chem Int Ed;45:5072-5129.
11. O'Shea R., Moser H.E. (2008) Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem;51:2871-2878.
12. Quinn R.J., Carroll A.R., Pham N.B., Baron P., Palframan M.E., Suraweera L., Pierens G.K., Muresan S. (2008) Developing a drug-like natural product library. J Nat Prod;71:464-468.
13. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev;46:3-26.
14. Royles B.J.L. (1995) Naturally-occurring tetramic acids - structure, isolation, and synthesis. Chem Rev;95:1981-2001.
15. Jeong Y.-C., Moloney M.G. (2011) Synthesis of and tautomerism in 3-acyltetramic acids. J Org Chem;76:1342-1354.
16. Andrews M.D., Brewster A.G., Crapnell K.M., Ibbett A.J., Jones T., Moloney M.G., Prout G., Watkin D. (1998) Regioselective Dieckmann cyclisations leading to enantiopure highly functionalised tetramic acid derivatives. J Chem Soc, Perkin Trans 1;1998:223-235.
17. Andrews M.D., Brewster A.G., Moloney M.G. (1996) Approaches towards the pyroglutamate skeleton of oxazolomycin. Synlett;1996:612-614.
18. Andrews M.D., Brewster A., Moloney M.G. (1994) A concise approach to functionalized, homochiral tetramic acids. Tetrahedron Asymmetry;5:1477-1478.
19. Anwar M., Cowley A.R., Moloney M.G. (2010) Novel chiral pyrrolidinone scaffolds derived from threonine with antibacterial activity. Tetrahedron Asymmetry;21:1758-1770.
20. Anwar M., Moloney M.G. (2007) Efficient enantioselective synthesis of tetramic acids and lactams from threonine. Tetrahedron Lett;48:7259-7262.
21. Jeong Y.-C., Moloney M.G. (2009) Tetramic acids as bioactive templates: synthesis, tautomeric and antibacterial behaviour. Synlett;15:2487-2491.
22. Bagwell C.L., Moloney M.G., Thompson A.L. (2008) On the antibiotic activity of oxazolomycin. Bioorg Med Chem Lett;18:4081-4086.
23. Bagwell C.L., Moloney M.G., Yaqoob M. (2010) Oxazolomycins: lead structures for novel antibiotics by click hybridisation. Bioorg Med Chem Lett;20:2090-2094.
24. Rees D.C., Congreve M., Murray C.W., Carr R. (2004) Fragment-based lead discovery. Nat Rev Drug Discov;3:660-672.
25. Congreve M., Carr R., Murray C., Jhoti H. (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today;8:876-877.
26. Feher M., Schmidt J.M. (2003) Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci;43:218-227.
27. Payne D.J., Gwynn M.N., Holmes D.J., Pompliano D.L. (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov;6:29-40.
28. Seebach D., Sting A.R., Hoffmann M. (1996) Self-regeneration of stereocenters (SRS) - applications, limitations, and abandonment of a synthetic principle. Angew Chem Int Ed Engl;35:2708-2748.
29. Zimmer H., Hillstrom W.W., Schmidt J.C., Seemuth P.D., Vogelli R. (1978) Substituted gamma-lactones 28. 3-(phenylmethylene)-2, 4(3h, 5h)-furandiones. J Org Chem;43:1541.
30. Henning H.-G., Gelbin A. (1993) Advances in tetramic acid chemistry. Adv Heterocycl Chem;57:139.
31. Pirc S., Bevk D., Jakše R., Rečnik S., Golič L., Golobič A., Meden A., Stanovnik B., Svete J. (2005) Synthesis of N-substituted 3-aminomethylidenetetramic acids. Synthesis;17:2969-2988.
32. Selic L., Stanovnik B. (2001) Dimethylamine substitution in N, N-dimethyl enamines. Synthesis of aplysinopsin analogues and 3-aminotetrahydrocoumarin derivatives. Tetrahedron;57:3159-3164.
33. Nolte M.J., Steyn P.S., Wessels P.L. (1980) Structural investigations of 3-acylpyrrolidine-2, 4-diones by nuclear magnetic-resonance spectroscopy and X-ray crystallography. J Chem Soc, Perkin Trans 1;1980:1057-1065.
34. Cottrell I.F., Davis P.J., Moloney M.G. (2004) Stereoselective oxygenation of bicyclic lactams. Tetrahedron Asymmetry;15:1239-1242.
35. Puri A.A., Bogyo M. (2009) Using small molecules to dissect mechanisms of microbial pathogenesis. ACS Chem Biol;4:603-616.
36. Frearson J.A., Collie I.T. (2009) HTS and hit finding in academia - from chemical genomics to drug discovery. Drug Discov Today;14:1150-1158.
37. Ferrara P., Apostolakis J., Caflisch A. (2002) Evaluation of a fast implicit solvent model for molecular dynamics simulations. Proteins;46:24-33.
38. Ertl P., Rohde B., Selzer P. (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem;43:3714-3717.
39. Ertl P. (2007) Polar surface area. In: Mannhold R., editor. Polar Surface Area. Weinheim: Wiley-VCH; p. 111-126.
40. Gleeson M.P. (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem;51:817-834.
41. Price D.A., Blagg J., Jones L., Greene N., Wager T. (2009) Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert Opin Drug Metab Toxicol;5:921-931.
42. Ho M.X., Hudson B.P., Das K., Arnold E., Ebright R.H. (2009) Structures of RNA polymerase-antibiotic complexes. Curr Opin Struct Biol;19:715-723.
43. Peukert S., Sun Y., Zhang R., Hurley B., Sabio M., Shen X., Gray C., Dzink-Fox J., Tao J., Cebula R., Wattanasin S. (2008) Design and structure-activity relationships of potent and selective inhibitors of undecaprenyl pyrophosphate synthase (UPPS): tetramic, tetronic acids and dihydropyridin-2-ones. Bioorg Med Chem Lett;18:1840-1844.
44. Ueda C., Tateda K., Horikawa M., Kimura S., Ishii Y., Nomura K., Yamada K., Suematsu T., Inoue Y., Ishiguro M., Miyairi S., Yamaguchi K. (2010) Anti-clostridium difficile potential of tetramic acid derivatives from pseudomonas aeruginosa quorum-sensing autoinducers. Antimicrob Agents Chemother;54:683-688.
45. Welch M., Mikkelsen H., Swatton J.E., Smith D., Thomas G.L., Glansdorp F.G., Spring D.R. (2005) Cell-cell communication in Gram-negative bacteria. Mol Biosyst;1:196-202.
46. Pitt W.R., Parry D.M., Perry B.G., Groom C.R. (2009) Heteroaromatic rings of the future. J Med Chem;52:2952-2963.
47. Lovering F., Bikker J., Humblet C. (2009) Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem;52:6752-6756.
48. Ritchie T.J., MacDonald S.J.F. (2009) The impact of aromatic ring count on compound developability - are too many aromatic rings a liability in drug design? Drug Discov Today;14:1011-1020.
49. MacCoss M., Baillie T.A. (2004) Organic chemistry in drug discovery. Science;303:1810-1813.
50. Hajduk P.J. (2006) Fragment-based drug design: how big is too big? J Med Chem;49:6972-6976.
51. Congreve M., Chessari G., Tisi D., Woodhead A.J. (2008) Recent developments in fragment-based drug discovery. J Med Chem;51:3661-3680.